Jin Cheng
Impact in
- Cancer Research top 1%
- MicroRNA in disease regulation
- Oncology top 1%
- Cytokine Signaling Pathways and Interactions
- Cancer-related Molecular Pathways
Papers in
-
- MicroRNA in disease regulation 7
- Oncology 31
- Cancer-related Molecular Pathways 9
- Cancer Cells and Metastasis 7
- Co-authors
- Domenico CoppolaRichard JoveMei SunJoseph R. TestaLing TianQian HuangJames TurksonSangkil Nam
- Journals
- Cancer Research (5 papers)Cancer Letters (3 papers)Nanoscale (3 papers)Genes Chromosomes and Cancer (3 papers)Oncogene (3 papers)
- Partner nations
- ChinaUnited StatesSpain
In The Last Decade
Jin Cheng
115 papers receiving 7.4k citations
Hit Papers
Peers
Comparison fields: 5 of 132
- Cancer Research 1.4k
- Oncology 2.1k
- Molecular Biology 4.2k
- Immunology 980
- Genetics 355
Countries citing papers authored by Jin Cheng
This map shows the geographic impact of Jin Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jin Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jin Cheng more than expected).
Fields of papers citing papers by Jin Cheng
This network shows the impact of papers produced by Jin Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jin Cheng. The network helps show where Jin Cheng may publish in the future.
Co-authors
The 25 scholars most cited alongside Jin Cheng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2023 | 2 | |
| 3 | 2022 | 50 | |
| 4 | 2021 | 58 | |
| 5 | 2020 | 24 | |
| 6 | 2019 | 38 | |
| 7 | 2019 | 42 | |
| 8 | 2019 | 8 | |
| 9 | 2019 | 19 | |
| 10 | 2018 | 13 | |
| 11 | 2017 | 17 | |
| 12 | miR-21 inhibits the effects of cyclooxygenase-2 inhibitor NS398 on apoptosis and invasion in gastric cancer cells | 2015 | 1 |
| 13 | Effect of Salvia Miltiorrhiza and Ligustrazine Injection in Combination with Traditional Chinese Medicine Enema on Chronic Kidney Disease and its Mechanism | 2013 | 0 |
| 14 | 2013 | 65 | |
| 15 | 2013 | 26 | |
| 16 | P53 enhances ascorbyl stearate-induced G2/M arrest of human ovarian cancer cells. | 2008 | 10 |
| 17 | [Expression of Twist in papillary thyroid carcinomas and its roles in differential diagnosis]. | 2008 | 1 |
| 18 | 2008 | 215 | |
| 19 | Dasatinib (BMS-354825), a novel multi-targeted kinase inhibitor that blocks tumor cell migration and invasion, is a promising therapeutic agent for metastatic prostate cancer | 2006 | 2 |
| 20 | Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways Hit paper breakdown → | 2005 | 489 |
About Jin Cheng
Jin Cheng is a scholar working on Cancer Research, Oncology, Molecular Biology, Genetics and Immunology, having authored 118 papers that have together received 7.5k indexed citations. Recurring topics across this work include Advanced biosensing and bioanalysis techniques (16 papers), RNA Interference and Gene Delivery (15 papers), Cell death mechanisms and regulation (12 papers), PI3K/AKT/mTOR signaling in cancer (10 papers), Cancer-related Molecular Pathways (9 papers), Nanoplatforms for cancer theranostics (9 papers), MicroRNA in disease regulation (7 papers) and Cancer Cells and Metastasis (7 papers). The work is most often cited by research in Cancer Research (1.4k citations), Oncology (2.1k citations), Molecular Biology (4.2k citations), Immunology (980 citations) and Genetics (355 citations). Jin Cheng has collaborated with scholars based in China, United States and Spain. Frequent co-authors include Domenico Coppola, Richard Jove, Mei Sun, Joseph R. Testa, Ling Tian, Qian Huang, James Turkson, Sangkil Nam, Sijia He and Chuan‐Yuan Li. Their work appears in journals such as Cancer Research, Cancer Letters, Nanoscale, Genes Chromosomes and Cancer and Oncogene.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.